| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
6 analysts have expressed a variety of opinions on Nurix Therapeutics (NASDAQ:NRIX) over the past quarter, offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 3 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 2 | 1 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $27.67, a high estimate of $34.00, and a low estimate of $16.00. Experiencing a 6.2% decline, the current average is now lower than the previous average price target of $29.50.
An in-depth analysis of recent analyst actions unveils how financial experts perceive Nurix Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Matthew Biegler | Oppenheimer | Lowers | Outperform | $30.00 | $32.00 |
| Terence Flynn | Morgan Stanley | Lowers | Equal-Weight | $16.00 | $17.00 |
| Robert Burns | HC Wainwright & Co. | Lowers | Buy | $34.00 | $36.00 |
| David Dai | UBS | Lowers | Buy | $26.00 | $30.00 |
| Matthew Biegler | Oppenheimer | Lowers | Outperform | $30.00 | $32.00 |
| Sudan Loganathan | Stephens & Co. | Maintains | Overweight | $30.00 | $30.00 |
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Nurix Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Nurix Therapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Nurix Therapeutics displayed positive results in 3M. As of 31 May, 2025, the company achieved a solid revenue growth rate of approximately 264.34%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -98.66%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Nurix Therapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -9.36%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -7.2%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.12.
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: NRIX
